Canada markets closed

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.70000.0000 (0.00%)
At close: 09:45AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.7000
Open0.7000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7000 - 0.7000
52 Week Range0.5450 - 2.6000
Volume100
Avg. Volume3
Market Cap27.022M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-1.1500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Poxel to Report Its 2023 Annual Results by the End of April 2024

    LYON, France, March 28, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces the publication at the end of April 2024 of its 2023 Annual Results, originally scheduled for April 9, 2024, given the expected completion of a transaction by the end of April.

  • Business Wire

    Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update

    LYON, France, February 15, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2023.

  • Business Wire

    Poxel Announces its Financial Calendar for 2024

    LYON, France, January 03, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024.